[1]张训男,彭春艳,李显东,等.冠心病并发高血压患者外周血白细胞SREBP-1 mRNA表达水平与脂质代谢紊乱的关系研究[J].现代检验医学杂志,2021,36(05):1-7.[doi:10.3969/j.issn.1671-7414.2021.05.001]
　ZHANG Xun-nan,PENG Chun-yan,LI Xian-dong,et al.Correlation Analysis between Leukocytes SREBP-1 mRNA Expression andSerum Lipids Level in Hypertensive Patients with Coronary Artery Disease[J].Journal of Modern Laboratory Medicine,2021,36(05):1-7.[doi:10.3969/j.issn.1671-7414.2021.05.001]
点击复制

冠心病并发高血压患者外周血白细胞SREBP-1 mRNA表达水平与脂质代谢紊乱的关系研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年05期
页码:
1-7
栏目:
论　著
出版日期:
2021-10-14

文章信息/Info

Title:
Correlation Analysis between Leukocytes SREBP-1 mRNA Expression andSerum Lipids Level in Hypertensive Patients with Coronary Artery Disease
文章编号:
1671-7414（2021）05-001-07
作者:
张训男1; 2; 彭春艳2; 李显东2; 张吉才2
（1. 锦州医科大学十堰市太和医院研究生培养基地，湖北医药学院附属医院，湖北十堰 442000；2. 十堰市太和医院检验科，湖北十堰 442000）
Author(s):
ZHANG Xun-nan1; 2;  PENG Chun-yan2;  LI Xian-dong2;  ZHANG Ji-cai2
（1. Postgraduate Training Base of Taihe Hospital of Shiyan City, Jinzhou Medical University, Hubei Shiyan 442000,China;2. Department of Laboratory Medicine, Taihe Hospital of Shiyan, Hubei Shiyan 442000，China）
关键词:
冠心病; 高血压; 固醇调解元件结合蛋白; 脂质代谢
分类号:
R541.4；R544.1；R392.11
DOI:
10.3969/j.issn.1671-7414.2021.05.001
文献标志码:
A
摘要:
目的　探讨冠心病并发高血压患者外周血白细胞固醇调节元件结合蛋白（sterol regulatory element binding proteins，SREBPs）的表达与脂质代谢紊乱的关系。方法　选取2017年6月~2018年5月在十堰市太和医院经冠脉造影确诊的196例冠心病患者，其中冠心病并发高血压患者126例，单纯冠心病患者70例，同期选取健康对照者178例。收取外周血，测定相关生化代谢指标，实时荧光定量PCR检测外周血白细胞中SREBPs（SREBP-1，SREBP-2）的mRNA表达水平。分析SREBP-1 mRNA表达水平与生化代谢指标及高血压的相关性，采用多因素Logistic回归分析法探究冠心病并发高血压的独立风险因素。ROC曲线分析SREBP-1对于冠心病并发高血压危险程度的预测价值。结果　单纯冠心病组及冠心病并发高血压组总胆固醇（TC）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、载脂蛋白A1（Apo-A1）和载脂蛋白B（Apo-B）水平均低于对照组，差异具有统计学意义（均P < 0.001）。相较于对照组及单纯冠心病组、冠心病并发高血压组SREBP-1 mRNA表达水平降低，差异有统计学意义（均P < 0.05）。相关性分析显示SREBP-1与TC，HDL-C，LDL-C，Apo-A1，Apo-B呈正相关（r = 0.207，0.216，0.121，0.246和0.114，均P < 0.05）。将对照组及冠心病并发高血压组SREBP-1分别与各组的舒张压及收缩压做相关性分析，两组研究对象中SREBP-1与舒张压及收缩压均无相关性（均P > 0.05）。多因素Logistic回归分析显示，校正年龄、性别、高脂血症及糖尿病之后，SREBP-1是冠心病并发高血压的独立风险因素，优势比（odds ratio，OR）= 0.210，95%可信区间（confidence interval，CI）= 0.079~0.561（P = 0.002）。SREBP-1作为冠心病并发高血压危险因素，ROC曲线分析显示，曲线下面积（area under the cure，AUC）为0.580 (0.503~0.657），敏感度和特异度分别为38.9%和77.0%（P = 0.045）。结论　SREBP-1表达水平在冠心病并发高血压患者外周血白细胞中显著降低，并与脂质代谢紊乱相关，可能成为潜在的冠心病并发高血压患者早期诊断的标志物。
Abstract:
Objective　To investigate the relation between the expression of sterol regulatory element binding proteins (SREBPs)and lipid metabolism disorder in hypertensive coronary artery disease (CAD). Methods　A total of 196 patients with CADdiagnosed by coronary angiography in Taihe Hospital from June 2017 to May 2018 were selected, including 126 hypertensiveCAD patients and 70 simple CAD patients, and 178 healthy controls were selected during the same period. Peripheral bloodsamples were collected and related biochemical metabolic indexes were detected. Total RNA was extracted and the mRNAexpression levels of SREBPs (SREBP-1, SREBP-2) were detected by real-time fluorescence quantitative PCR. The correlationbetween SREBP-1 mRNA expression level and biochemical metabolic indexes and hypertension was analyzed. MultivariateLogistic regression analysis was used to explore the independent risk factors for hypertensive CAD patients. The predictive valueof SREBP-1 for the risk degree of hypertensive CAD patients was analyzed by ROC curve. Results　The levels of total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein A1(Apo-A1) and apolipoprotein B (Apo-B) in simple CAD and hypertensive CAD group were lower than those in healthy controls,and the differences were statistically significant (all P < 0.001). Compared with healthy controls and simple CAD patients, theexpression of SREBP-1 was down-regulated in hypertensive CAD patients and the difference was statistically significant (all P <0.05). Correlation analysis showed that SREBP-1 was positively correlated with TC, HDL-C, LDL-C, Apo-A1 and Apo-B (r =0.207, 0.216, 0.121, 0.246 and 0.114, all P < 0.05).The correlation between SREBP-1 and diastolic blood pressure and systolicblood pressure in control group and hypertensive CAD group were analyzed. There was no correlation between SREBP-1 anddiastolic blood pressure and systolic blood pressure in two groups (all P > 0.05). After adjustment for age, gender, hyperlipidemiaand diabetes, multivariate regression analysis revealed that SREBP-1 was an independent risk factor for hypertensive CAD , oddsratio (OR) = 0.210, 95% confidence interval (CI) = 0.079~0.561 (P = 0.002). The ROC curve analysis showed that SREBP-1 wasa risk factor for hypertensive CAD, area under the curve (AUC) = 0.580 (0.503~0.657), sensitivity and specificity were 38.90%and 77.0% (P = 0.045), respectively. Conclusion　The expression level of SREBP-1 in peripheral blood leukocytes in patientswith hypertensive CAD was significantly decreased, which was associated with lipid metabolism disorders and may be a potentialdiagnostic and/or therapeutic biomarker for hypertensive CAD.

参考文献/References:

[1] MALAKAR A K, CHOUDHURY D, HALDER B, etal. A review on coronary artery disease, its risk factors,and therapeutics[J]. Journal of Cellular Physiology,2019, 234(10): 16812-16823.
[2] 张阳东，周建荣，楚瑞雪，等．血管紧张素Ⅱ 1 型受体3 个单核苷酸多态性与冠心病的相关性分析[J].现代检验医学杂志，2017, 32(2): 57-59.ZHANG Yangdong, ZHOU Jianrong, CHU Ruixue,et al. Correlation between the three single nucleotidepolymorphisms in angiotensin Ⅱ type one receptorgene and coronary artery disease [J]. Journal of ModernLaboratory Medicine, 2017, 32(2): 57-59.
[3] 汪莲开. 老年高血压患者发生心血管事件相关危险因素[J]. 中国老年学杂志, 2012, 32(6): 1280-1281.WANG Liankai. Risk factors of cardiovascular eventsin elderly patients with hypertension[J]. ChineseJournal of Gerontology, 2012, 32(6): 1280-1281.
[4] AMPUT P, MCSWEENEY C, PALEE S, et al. Theeffects of proprotein convertase subtilisin/kexin type9 inhibitors on lipid metabolism and cardiovascularfunction[J]. Biomedicine & Pharmacotherapy, 2019,109: 1171-1180.
[5] 郭丹，王福莉，陶黎莉. 糖尿病患者脂质代谢紊乱的特点及治疗对策[J]. 中国医药指南,2019, 17 (22):122-123.GUO Dan, WANG Fuli, TAO Lili. Characteristicsand treatment of lipid metabolism disorder in diabeticpatients[J]. Guide of China Medicine, 2019, 17(22):122-123.
[6] SHIMANO H. Sterol regulatory element-bindingproteins (SREBPs): transcriptional regulators of lipidsynthetic genes[J]. Progress in Lipid Research, 2001,40(6): 439-452.
[7] JIANG Tao, ZHANG Guangli, LOU Zhaohuan. Role ofthe sterol regulatory element binding protein pathwayin tumorigenesis[J]. Frontiers in Oncology, 2020, 10:1788.
[8] SOBATI S, SHAKOURI A, EDALATI M, et al.PCSK9: A key target for the treatment of cardiovasculardisease (CVD)[J]. Advanced Pharmaceutical Bulletin,2020, 10(4): 502-511.
[9] ZHAO Zifeng, YIN Lei, WU Feihua, et al. Hepaticmetabolic regulation by nuclear factor E4BP4[J].Journal of Molecular Endocrinology, 2021, 66(1):R15-R21.
[10] 中国高血压防治指南修订委员会, 高血压联盟( 中国), 中华医学会心血管病学分会, 等. 中国高血压防治指南(2018 年修订版)[J]. 中国心血管杂志,2019, 24 (1): 24-56.Chinese Hypertension League, Chinese Society ofCardiology, Chinese Medical Doctor AssociationHypertension Committee, Hypertension Branchof China International Exchange and PromotiveAssociation for Medical and Health Care, HypertensionBranch of Chinese Geriatric Medical Association，et al . 2018 Chinese guidelines for the management ofhypertension [J]. Chin J Cardiovasc Med, 2019,24(1):24-56.
[11] 中国成人血脂异常防治指南修订联合委员会．中国成人血脂异常防治指南(2016 年修订版)[J]．中国循环杂志, 2016, 31(10): 937-953.Joint Committee Issued Chinese Guideline for theManagement of Dyslipidemia.2016 Chinese guidelinefor the management of dyslipidemia in adults [J].Chinese Circulation Journal, 2016, 31(10): 937-953.
[12] 李苗苗，王玉红，刘静．中国沈阳地区汉族冠心病患者CYP2C19 基因多态性分布特征[J]．现代检验医学杂志，2019, 34(2): 5-8,13.LI Miaomiao, WANG Yuhong, LIU Jing. Distributioncharacteristics of CYP2C19 gene polymorphism in hanpatients with coronary heart disease in Shenyang,China[J]. Journal of Modern Laboratory Medicine, 2019,34(2): 5-8,13.
[13] 陈青文，李丹丹．冠心病患者外周血中性粒细胞/淋巴细胞比值与冠脉狭窄程度的相关性研究[J]．现代检验医学杂志, 2020, 35(6): 98-101.CHEN Qingwen, LI Dandan. Correlation betweenthe degree of coronary stenosis and the neutrophil/lymphocyte ratio in patients with coronary arterydisease [J]. Journal of Modern Laboratory Medicine,2020, 35(6): 98-101.
[14] ZHANG Xiao, ZHANG Puhong, GAO Jialin, et al.Autophagy dysregulation caused by ApoM deficiencyplays an important role in liver lipid metabolicdisorder[J]. Biochemical and Biophysical ResearchCommunications, 2018, 495(4): 2643-2648.
[15] MAHMOOD S, BIRKAYA B, RIDEOUT T C, etal. Lack of mitochondria-generated acetyl-CoA bypyruvate dehydrogenase complex downregulates geneexpression in the hepatic de novo lipogenic pathway[J].American Journal of Physiology-Endocrinology andMetabolism, 2016, 311(1): E117-E127.
[16] PANG Bo, ZHANG Juanjuan, ZHANG Xi, et al.Inhibition of lipogenesis and induction of apoptosis byvalproic acid in prostate cancer cells via the C/EBPα/SREBP-1 pathway[J]. Acta Biochimica et BiophysicaSinica, 2021, 53(3): 354-364.
[17] KUAN Y C, TAKAHASHI Y, MARUYAMA T, etal. Ring finger protein 5 activates sterol regulatoryelement-binding protein 2 (SREBP2) to promotecholesterol biosynthesis via inducing polyubiquitinationof SREBP chaperone SCAP[J].The Journal ofBiological Chemistry, 2020, 295(12): 3918-3928.
[18] OTENG A B, LOREGGER A, VAN WEEGHEL M,et al. Industrial trans fatty acids stimulate SREBP2-Mediated cholesterogenesis and promote Non-Alcoholic fatty liver disease[J]. Molecular Nutrition &Food Research, 2019, 63(19): e1900385.
[19] LIU Wen, ZHAI Chengkai, ZHANG Xiaoqiang, etal. Research of the whole grain-soybean compoundpackage to regulate the cholesterol metabolism bySREBP-2, LDLR and visfatin[J]. Journal of HygieneResearch, 2013, 42(2) : 196-202.
[20] SONG Ziyi, XIAOLI A M, YANG Fajun. Regulationand metabolic significance of De Novo lipogenesis inadipose tissues[J]. Nutrients, 2018, 10(10): 1383.
[21] CHEUNG B M Y, WAT N M S, MAN Y B, et al.Relationship between the metabolic syndrome andthe development of hypertension in the Hong KongCardiovascular Risk Factor Prevalence Study-2(CRISPS2)[J]. American Journal of Hypertension,2008, 21(1): 17-22.
[22] HU Jun, ZHU Fu, XIE Jun, et al. Structural andfunctional changes of the coronary arteries in elderlysenile patients with essential hypertension[J]. MolecularMedicine Reports, 2013, 8(5) : 1385-1389.
[23] HALPERIN R O, SESSO H D, MA Jing, et al.Dyslipidemia and the risk of incident hypertension inmen[J]. Hypertension, 2006, 47(1): 45-50.
[24] VALLE R J, MAURO A G, DEVARAKONDA T,et al. Reperfusion therapy with recombinant humanrelaxin-2 (Serelaxin) attenuates myocardial infarctsize and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism[J].Cardiovascular Research, 2017, 113(6): 609-619.
[25] WANG Dong, LUO Yuhuan, MYAKALA K, et al.Serelaxin improves cardiac and renal function inDOCA-salt hypertensive rats[J]. Scientific Reports,2017, 7(1): 9793.
[26] YANG Yide, SONG Yeyun, WANG Shuo, et al. Geneticvariations in sterol regulatory element binding proteincleavage-activating protein (SCAP) are associated withblood pressure in overweight/obese Chinese children[J].PLoS One, 2017, 12(5): e0177973.
[27] KHARITONENKOV A, SHIYANOVA T L, KOESTERA, et al. FGF-21 as a novel metabolic regulator[J]. TheJournal of Clinical Investigation, 2005, 115(6): 1627-1635.
[28] 朱升龙, 任桂萍, 张振宇, 等. 成纤维细胞生长因子21 对胰岛素抵抗所致高血压的治疗作用[J]. 药学学报,2013,48(9):1409-1414.ZHU Shenglong, REN Guiping, ZHANG Zhenyu, etal. Therapeutic effect of fibroblast growth factor 21on hypertension induced by insulin resistance[J]. ActaPharmaceutica Sinica,2013,48(9):1409-1414.
[29] HUANG Zhe, XU Aimin, CHEUNG Bemard M Y. Thepotential role of fibroblast growth factor 21 in lipidmetabolism and hypertension[J]. Current HypertensionReports, 2017, 19(4): 28.
[30] LEE J, JUNG S, KIM N, et al. Myocardial metabolicalterations in mice with diet-induced atherosclerosis:linking sulfur amino acid and lipid metabolism[J].Scientific Reports, 2017, 7(1) : 801-809.

相似文献/References:

[1]韩瑞玲,李 艳,吴 薇.武汉地区冠心病患者氯吡格雷药物代谢相关基因CYP2C19的多态性分布分析[J].现代检验医学杂志,2015,30(03):21.[doi:10.3969/j.issn.1671-7414.2015.03.006]
　HAN Rui-ling,LI Yan,WU Wei.Analysis of the Polymorphism Distribution of Clopidogrel Metabolism Related Gene CYP2C19 in Patients with Coronary Artery Disease in Wuhan[J].Journal of Modern Laboratory Medicine,2015,30(05):21.[doi:10.3969/j.issn.1671-7414.2015.03.006]
[2]洪骏,王锋,印中鹏,等.冠心病患者血浆纤维蛋白原与脂蛋白相关磷脂酶A2水平[J].现代检验医学杂志,2015,30(05):6.[doi:10.3969/j.issn.1671-7414.2015.05.003]
　HONG Jun,WANG Feng,YIN Zhong-peng,et al.Levels of Plasma Lipoprotein Associated Phospholipase A2 and Fibrinogen in Patients with Coronary Artery Disease[J].Journal of Modern Laboratory Medicine,2015,30(05):6.[doi:10.3969/j.issn.1671-7414.2015.05.003]
[3]赵佳a,姚创利a,左林,等.冠心病患者血清同型半胱氨酸对血脂和锰超氧化物歧化酶的影响[J].现代检验医学杂志,2015,30(05):44.[doi:10.3969/j.issn.1671-7414.2015.05.013]
　ZHAO Jiaa,YAO Chuang-lia,ZUO Lin,et al.Effects of Homocysteine on Blood Lipid and Manganese Superoxide Dismutase in Patients with Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2015,30(05):44.[doi:10.3969/j.issn.1671-7414.2015.05.013]
[4]李 垚,杨 平.早发冠心病触珠蛋白水平及其在免疫调节中的作用研究[J].现代检验医学杂志,2015,30(01):98.[doi:10.3969/j.issn.1671-7414.2015.01.027]
　LI Yao,YANG Ping.Role of Haptoglobin in the Immunomodulatory in Patients with Premature Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2015,30(05):98.[doi:10.3969/j.issn.1671-7414.2015.01.027]
[5]张 蕾,陈 捷,陈玉婷.冠心病并发恶性肿瘤患者Ghrelin/obestatin比值变化及意义[J].现代检验医学杂志,2016,31(04):104.[doi:10.3969/j.issn.16717-414.2016.04.029]
　ZHANG Lei,CHEN Jie,CHEN Yu-ting.Change and Significance of Ghrelin/Obestatin in Patients with Coronary Heart Disease Complicated with Malignant Tumor[J].Journal of Modern Laboratory Medicine,2016,31(05):104.[doi:10.3969/j.issn.16717-414.2016.04.029]
[6]赵 佳,左 林,姚创利,等.冠心病患者血清同型半胱氨酸水平与氧化应激的关系研究[J].现代检验医学杂志,2016,31(05):27.[doi:10.3969/j.issn.1671-7414.2016.05.007]
　ZHAO Jia,ZUO Lin,YAO Chuang-li,et al.Study on the Relationship between Serum Homocysteine Levels and Oxidative Stress in Patients with Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2016,31(05):27.[doi:10.3969/j.issn.1671-7414.2016.05.007]
[7]姚创利,黎 阳,鲁旭娟,等.超氧化物歧化酶及其同工酶和超敏C-反应蛋白与冠心病的关系[J].现代检验医学杂志,2016,31(05):73.[doi:10.3969/j.issn.1671-7414.2016.05.019]
　YAO Chuang-li,LI Yang,LU Xu-juan,et al.Relationship of Superoxide Dismutase Isoenzyme and High Sensitive C-Reactive Protein with Coronary Heart Disease[J].Journal of Modern Laboratory Medicine,2016,31(05):73.[doi:10.3969/j.issn.1671-7414.2016.05.019]
[8]黄生金,郑利平,陆俊佳,等.广西地区壮族和汉族冠心病患者胱抑素C水平及其基因多态性的比较研究[J].现代检验医学杂志,2017,32(03):26.[doi:10.3969/j.issn.1671-7414.2017.03.007]
　HUANG Sheng-jin,ZHENG Li-ping,LU Jun-jia,et al.Comparative Study of Cystatin C and Its Gene Polymorphism of Pati ents with Coronary Heart Disease between Zhuang and Han in Guangxi Region[J].Journal of Modern Laboratory Medicine,2017,32(05):26.[doi:10.3969/j.issn.1671-7414.2017.03.007]
[9]王跃帮,吴 娟,崔 倩,等.IL-6基因启动子区域-572C>G和-174G>C多态性与江苏宿迁汉族人群冠心病的相关性[J].现代检验医学杂志,2018,33(03):31.[doi:10.3969/j.issn.1671-7414.2018.03.010]
　WANG Yue-bang,WU Juan,CUI Qian,et al.Association between Interleukin-6-572C>G and -174G>C Gene Polymorphism in the Promoter Region and Coronary Heart Disease of Han Population in Suqian of Jiangsu[J].Journal of Modern Laboratory Medicine,2018,33(05):31.[doi:10.3969/j.issn.1671-7414.2018.03.010]
[10]刘亚东,冯莉莉,王海晶,等.冠心病患者血清Lp-PLA2与HCY检测及其与冠状动脉病变程度的相关性分析[J].现代检验医学杂志,2018,33(06):83.[doi:10.3969/j.issn.1671-7414.2018.06.022]
　LIU Ya-dong,FENG Li-li,WANG Hai-jing,et al.Detection of Serum Lp-PLA2 and HCY in Patients with Coronary Heart Disease and Its Correlation with the Degree of Coronary Artery Disease[J].Journal of Modern Laboratory Medicine,2018,33(05):83.[doi:10.3969/j.issn.1671-7414.2018.06.022]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金资助项目(81600358)；湖北省科技厅面上项目(2019CFB434)。
作者简介：张训男（1994-），女，硕士，初级技师，主要研究方向：临床检验诊断学，E-mail：1210050453@qq.com。
通讯作者：张吉才，男，教授，主任技师,E-mail：3561361@qq.com。
更新日期/Last Update: 1900-01-01